Table 3.

Hazard risk for all cancer mortality in patients with low handgrip strength stratified by sex and age

Mortality	HR	95% CI	P values	Mortality	HR	95% CI	P values
Women				Men
<60				<60
Model 0	1.441	1.212 to 1.715	<0.001 a	Model 0	2.381	1.920 to 2.952	<0.001 a
Model 1	1.279	1.066 to 1.536	0.008 a	Model 1	1.596	1.256 to 2.028	<0.001 a
Model 2	1.335	1.109 to 1.608	0.002 a	Model 2	1.506	1.180 to 1.922	0.001 a
Model 3	1.337	1.107 to 1.615	0.003 a	Model 3	1.487	1.156 to 1.912	0.002 a
60–75				60–75
Model 0	1.408	1.155 to 1.716	<0.001 a	Model 0	1.681	1.429 to 1.978	<0.001 a
Model 1	1.372	1.114 to 1.691	0.003 a	Model 1	1.319	1.104 to 1.576	0.002 a
Model 2	1.340	1.086 to 1.654	0.006 a	Model 2	1.339	1.117 to 1.607	0.002 a
Model 3	1.324	1.062 to 1.652	0.013 a	Model 3	1.298	1.074 to 1.568	0.007 a
≥75				≥75
Model 0	1.400	0.856 to 2.291	0.180	Model 0	1.455	1.084 to 1.952	0.012 a
Model 1	1.270	0.725 to 2.225	0.403	Model 1	1.039	0.739 to 1.463	0.824
Model 2	1.606	0.889 to 2.901	0.116	Model 2	1.113	0.783 to 1.582	0.551
Model 3	1.965	0.887 to 4.352	0.096	Model 3	1.065	0.716 to 1.585	0.755

CI, confidence interval; HR, hazard ratio.

Model 0 was unadjusted. Model 1 was adjusted for age, gender, body mass index, albumin, haemoglobin, weight loss, Karnofsky performance scores, nutritional risk screening 2002, patient‐generated subjective global assessment scores, physical activity, intake status, mid‐arm circumference, triceps skinfold thickness, maximum calf girth, smoking, alcohol drinking, and tea drinking. Model 2 was adjusted for Model 1 plus previous treatments, types of chemotherapy, and cancer stages. Model 3 was adjusted for Model 2 plus cancer types, quality of life, and comorbidities.

^aData reach statistical significance.